Skip to main content

Table 2 Baseline characteristics of subjects

From: Effects of pravastatin, phytosterols, and combination therapy on lipid profile in HIV-infected patients: an open-labelled, randomized cross-over study

 

Mean ± SD or median (min,max) or number (%)

p value

Group 1 (n = 11)

Group 2 (n = 9)

Group 3 (n = 8)

Group 4 (n = 8)

Age, year

47.94 ± 7.73

45.33 ± 8.66

41.12 ± 7.72

43.00 ± 7.41

0.23b

BMI, kg/m2

22.48 ± 2.40

22.68 ± 3.64

23.63 ± 3.07

21.61 ± 2.45

0.59b

Male, no.

8 (72.7)

7 (77.8)

4 (50)

4 (50)

0.48c

Diabetes, no.

0

1 (11.1)

0

0

0.41c

Hypertension, no

1 (9.1)

1 (11.1)

0

0

0.48c

PIs, no.

2 (18.2)

1 (11.1)

0

1 (12.5)

0.50c

NNRTI, no.

9 (81.8)

8 (88.9)

8 (100)

7 (87.5)

Suppressed HIV viral load, nod

9 (81.8)

8 (88.9)

8 (100)

8 (100)

0.27c

HIV duration, years

5.61 ± 5.21

11.11 ± 3.79

6.61 ± 4.51

8.78 ± 7.11

0.13b

CD4, cell/cmm

514.27 ± 331.71

678.22 ± 438.85

612.62 ± 270.87

443.88 ± 152.96

0.45b

Creatinine, mg/dL

0.90 ± 0.19

0.95 ± 0.28

0.94 ± 0.35

0.73 ± 0.13

0.29b

SGPT, mg/dL

35.81 ± 24.46

35.66 ± 15.02

30.13 ± 12.77

27.50 ± 8.18

0.67b

HDL-c, mg/dL

52.07 ± 13.23

53.04 ± 12.08

57.73 ± 20.93

58.13 ± 23.15

0.83b

LDL-c, mg/dL

175.75 ± 36.90

186.99 ± 24.60

163.01 ± 9.65

173.04 ± 35.24

0.43b

TC, mg/dL

222.0 (197,301)

245.0 (227,353)

242.5 (191,285)

242.0 (202,297)

0.48a

TG, mg/dL

134.0 (64,390)

176.00 (53,620)

106.50 (58,499)

109.0 (52,367)

0.54a

CPK, mg/dL

131.0 (46,876)

150.0 (87,234)

133.5 (60,289)

123.0 (79,532)

0.96a

  1. Group 1, pravastatin then combination; Group 2, combination then pravastatin; Group 3, phytosterols then combination; Group 4, combination then phytosterols.
  2. aKruskal–Wallis Test.
  3. bOne-way ANOVA.
  4. cLikelihood Ratio test.
  5. dSuppressed HIV viral load defined by HIV viral load <50 copies/ml.